1
|
He H, Liang L, Han D, Xu F, Lyu J. Different Trends in the Incidence and Mortality Rates of Prostate Cancer Between China and the USA: A Joinpoint and Age-Period-Cohort Analysis. Front Med (Lausanne) 2022; 9:824464. [PMID: 35187007 PMCID: PMC8850968 DOI: 10.3389/fmed.2022.824464] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2021] [Accepted: 01/05/2022] [Indexed: 12/25/2022] Open
Abstract
Purpose This study used data from the Global Burden of Disease Study 2019 (GBD 2019) to determine the differences in the incidence and mortality of prostate cancer (PCa) between China and the USA from 1990 to 2019. Method The age-standardized incidence rates (ASIRs) and age-standardized death rates (ASDRs) in China and the USA from 1990 to 2019 were extracted from GBD 2019. Annual percentage changes and relative risks of ASIR and ASDR were calculated using joinpoint regression analysis and age-period-cohort models, respectively. Results The ASIR of PCa in China continually increased from 1990 to 2019, while in the USA it increased from 1990 to 1994 and then continually decreased until 2015, and then slightly increased again until 2019. The ASDR in China did not change, and the trend of ASDR in the USA was similar to the trend of the ASIR in the USA. The incidence of PCa increased with age in China, but decreased after the age of 75 years in the USA. A period effect was present, with the risk of developing PCa increasing continuously over longer time periods. Those born later had a lower risk of PCa or death, indicating a cohort effect. Conclusion PCa is becoming more problematic for Chinese males. Disease trends in the USA indicate that large-scale screening may be beneficial and should be immediately implemented among high-risk groups in China.
Collapse
Affiliation(s)
- Hairong He
- Clinical Research Center, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.,School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, China
| | - Liang Liang
- Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
| | - Didi Han
- School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, China
| | - Fengshuo Xu
- School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, China
| | - Jun Lyu
- Clinical Research Center, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.,School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, China.,Department of Clinical Research, The First Affiliated Hospital of Jinan University, Guangzhou, China
| |
Collapse
|
2
|
Saunders EJ, Kote-Jarai Z, Eeles RA. Identification of Germline Genetic Variants that Increase Prostate Cancer Risk and Influence Development of Aggressive Disease. Cancers (Basel) 2021; 13:760. [PMID: 33673083 PMCID: PMC7917798 DOI: 10.3390/cancers13040760] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2020] [Revised: 02/08/2021] [Accepted: 02/09/2021] [Indexed: 12/15/2022] Open
Abstract
Prostate cancer (PrCa) is a heterogeneous disease, which presents in individual patients across a diverse phenotypic spectrum ranging from indolent to fatal forms. No robust biomarkers are currently available to enable routine screening for PrCa or to distinguish clinically significant forms, therefore late stage identification of advanced disease and overdiagnosis plus overtreatment of insignificant disease both remain areas of concern in healthcare provision. PrCa has a substantial heritable component, and technological advances since the completion of the Human Genome Project have facilitated improved identification of inherited genetic factors influencing susceptibility to development of the disease within families and populations. These genetic markers hold promise to enable improved understanding of the biological mechanisms underpinning PrCa development, facilitate genetically informed PrCa screening programmes and guide appropriate treatment provision. However, insight remains largely lacking regarding many aspects of their manifestation; especially in relation to genes associated with aggressive phenotypes, risk factors in non-European populations and appropriate approaches to enable accurate stratification of higher and lower risk individuals. This review discusses the methodology used in the elucidation of genetic loci, genes and individual causal variants responsible for modulating PrCa susceptibility; the current state of understanding of the allelic spectrum contributing to PrCa risk; and prospective future translational applications of these discoveries in the developing eras of genomics and personalised medicine.
Collapse
Affiliation(s)
- Edward J. Saunders
- The Institute of Cancer Research, London SM2 5NG, UK; (Z.K.-J.); (R.A.E.)
| | - Zsofia Kote-Jarai
- The Institute of Cancer Research, London SM2 5NG, UK; (Z.K.-J.); (R.A.E.)
| | - Rosalind A. Eeles
- The Institute of Cancer Research, London SM2 5NG, UK; (Z.K.-J.); (R.A.E.)
- Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK
| |
Collapse
|
3
|
Tong Y, Tang Y, Li S, Zhao F, Ying J, Qu Y, Niu X, Mu D. Cumulative evidence of relationships between multiple variants in 8q24 region and cancer incidence. Medicine (Baltimore) 2020; 99:e20716. [PMID: 32590746 PMCID: PMC7328976 DOI: 10.1097/md.0000000000020716] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/14/2023] Open
Abstract
Genome-wide association studies (GWAS) have identified multiple independent cancer susceptibility loci at chromosome 8q24. We aimed to evaluate the associations between variants in the 8q24 region and cancer susceptibility. A comprehensive research synopsis and meta-analysis was performed to evaluate associations between 28 variants in 8q24 and risk of 7 cancers using data from 103 eligible articles totaling 146,932 cancer cases and 219,724 controls. Results: 20 variants were significantly associated with risk of prostate cancer, colorectal cancer, thyroid cancer, breast cancer, bladder cancer, stomach cancer, and glioma, including 1 variant associated with prostate cancer, colorectal cancer, and thyroid cancer. Cumulative epidemiological evidence of an association was graded as strong for DG8S737 -8 allele, rs10090154, rs7000448 in prostate cancer, rs10808556 in colorectal cancer, rs55705857 in gliomas, rs9642880 in bladder cancer, moderate for rs16901979, rs1447295, rs6983267, rs7017300, rs7837688, rs1016343, rs620861, rs10086908 associated in prostate cancer, rs10505477, rs6983267 in colorectal cancer, rs6983267 in thyroid cancer, rs13281615 in breast cancer, and rs1447295 in stomach cancer, weak for rs6983561, rs13254738, rs7008482, rs4242384 in prostate cancer. Data from ENCODE suggested that these variants with strong evidence and other correlated variants might fall within putative functional regions. Our study provides summary evidence that common variants in the 8q24 are associated with risk of multiple cancers in this large-scale research synopsis and meta-analysis. Further studies are needed to explore the mechanisms underlying variants in the 8q24 involved in various human cancers.
Collapse
Affiliation(s)
- Yu Tong
- Department of Pediatrics
- Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education
| | - Ying Tang
- Department of Pediatrics
- Department of Diagnostic Ultrasound
| | - Shiping Li
- Department of Pediatrics
- Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education
| | - Fengyan Zhao
- Department of Pediatrics
- Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education
| | - Junjie Ying
- Department of Pediatrics
- Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education
| | - Yi Qu
- Department of Pediatrics
- Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education
| | - Xiaoyu Niu
- Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education
- Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, Sichuan Province, China
| | - Dezhi Mu
- Department of Pediatrics
- Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education
| |
Collapse
|
4
|
Chen Z, Lin X, Lei Y, Chen H, Finnell RH, Wang Y, Xu J, Lu D, Xie H, Chen F. Genome-wide association study in Chinese cohort identifies one novel hypospadias risk associated locus at 12q13.13. BMC Med Genomics 2019; 12:196. [PMID: 31856834 PMCID: PMC6923877 DOI: 10.1186/s12920-019-0642-0] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2018] [Accepted: 12/04/2019] [Indexed: 12/21/2022] Open
Abstract
Background Hypospadias risk–associated gene variants have been reported in populations of European descent using genome-wide association studies (GWASs). There is little known at present about any possible hypospadias risk associations in Han Chinese populations. Methods To systematically investigate hypospadias risk–associated gene variants in Chinese patients, we performed the first GWAS in a Han Chinese cohort consisting of 197 moderate-severe hypospadias cases and 933 unaffected controls. Suggestive loci (p < 1 × 10− 4) were replicated in 118 cases and 383 controls, as well as in a second independent validation population of 137 cases and 190 controls. Regulatory and protein-protein interactions (PPIs) were then conducted for the functional analyses of candidate variants. Results We identified rs11170516 with the risk allele G within the SP1/SP7 region that was independently associated with moderate-severe hypospadias [SP1/SP7, rs11170516, Pcombine = 3.5 × 10− 9, odds ratio (OR) = 1.96 (1.59–2.44)]. Results also suggested that rs11170516 is associated with the expression of SP1 as a cis-expression quantitative trait locus (cis-eQTL). Protein SP1 could affect the risk of hypospadias via PPIs. Conclusions We performed the first GWAS of moderate-severe hypospadias in a Han Chinese cohort, and identified one novel susceptibility cis-acting regulatory locus at 12q13.13, which may regulate a variety of hypospadias-related pathways by affecting proximal SP1 gene expression and subsequent PPIs. This study complements known common hypospadias risk-associated variants and provides the possible role of cis-acting regulatory variant in causing hypospadias.
Collapse
Affiliation(s)
- Zhongzhong Chen
- Department of Urology, Shanghai Children's Hospital, Shanghai Jiao Tong University, Shanghai, 200062, China
| | - Xiaoling Lin
- State Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University, Shanghai, 200438, China.,Department of Urology, Huashan Hospital, Fudan University, Shanghai, 200040, China
| | - Yunping Lei
- Center for Precision Environmental Health, Departments of Molecular and Cellular Biology and Medicine, Baylor College of Medicine, Houston, TX, 77030, USA
| | - Haitao Chen
- State Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University, Shanghai, 200438, China
| | - Richard H Finnell
- Center for Precision Environmental Health, Departments of Molecular and Cellular Biology and Medicine, Baylor College of Medicine, Houston, TX, 77030, USA
| | - Yaping Wang
- Department of Urology, Shanghai Children's Hospital, Shanghai Jiao Tong University, Shanghai, 200062, China
| | - Jianfeng Xu
- State Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University, Shanghai, 200438, China.,Department of Urology, Huashan Hospital, Fudan University, Shanghai, 200040, China
| | - Daru Lu
- State Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University, Shanghai, 200438, China.
| | - Hua Xie
- Department of Urology, Shanghai Children's Hospital, Shanghai Jiao Tong University, Shanghai, 200062, China.
| | - Fang Chen
- Department of Urology, Shanghai Children's Hospital, Shanghai Jiao Tong University, Shanghai, 200062, China. .,Department of Urology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, 200233, China. .,Shanghai Eastern Urological Reconstruction and Repair institute, Shanghai, 200233, China.
| |
Collapse
|
5
|
Ha Chung B, Horie S, Chiong E. The incidence, mortality, and risk factors of prostate cancer in Asian men. Prostate Int 2018; 7:1-8. [PMID: 30937291 PMCID: PMC6424686 DOI: 10.1016/j.prnil.2018.11.001] [Citation(s) in RCA: 53] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2018] [Revised: 10/07/2018] [Accepted: 11/12/2018] [Indexed: 01/23/2023] Open
Abstract
The objective of this review was to describe the epidemiology and risk factors of prostate cancer (PCa) in Asian populations. English language publications published over the last 10 years covering studies on the incidence, mortality, and risk factors of PCa in Asia were reviewed. The incidence of PCa in Asia is rising but is still significantly lower than that in Western countries. Studies in Asia indicated that the consumption of red meat, fat, dairy, and eggs was associated with a higher risk for PCa. Age and family history were also found to be risk factors. The emergence of genetic data indicates that different genetic backgrounds between Asian and Western populations play a role in the observed differences in PCa incidence. The lower incidence of PCa in Asian men than in Western men may in part be due to a lack of systematic prostate-specific antigen screening, but environmental and genetic factors also play a role.
Collapse
Affiliation(s)
- Byung Ha Chung
- Department of Urology, Yonsei University College of Medicine, 211 Eonju-ro, Gangnam-gu, Seoul, 135-720, Republic of Korea
| | - Shigeo Horie
- Department of Urology, Juntendo University Graduate School of Medicine, 2 Chome-1-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - Edmund Chiong
- Department of Urology, National University Hospital, National University Health System, 5 Lower Kent Ridge Road, 119074, Singapore
| |
Collapse
|
6
|
Tong Y, Yu T, Li S, Zhao F, Ying J, Qu Y, Mu D. Cumulative Evidence for Relationships Between 8q24 Variants and Prostate Cancer. Front Physiol 2018; 9:915. [PMID: 30061842 PMCID: PMC6055007 DOI: 10.3389/fphys.2018.00915] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2018] [Accepted: 06/22/2018] [Indexed: 11/25/2022] Open
Abstract
Multiple independent cancer susceptibility loci at chromosome 8q24 have been identified by GWAS (Genome-wide association studies). Forty six articles including 60,293 cases and 62,971 controls were collected to conduct a meta-analysis to evaluate the associations between 21 variants in 8q24 and prostate cancer risk. Of the 21 variants located in 8q2\5 were significantly associated with the risk of prostate cancer. In particular, both homozygous AA and heterozygous CA genotypes of rs16901979, as well as the AA and CA genotypes of rs1447295, were associated with the risk of prostate cancer. Our study showed that variants in the 8q24 region are associated with prostate cancer risk in this large-scale research synopsis and meta-analysis. Further studies are needed to explore the role of the 8q24 variants involved in the etiology of prostate cancer.
Collapse
Affiliation(s)
- Yu Tong
- Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China.,Key Laboratory of Obstetric & Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, China
| | - Tao Yu
- Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China.,Key Laboratory of Obstetric & Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, China
| | - Shiping Li
- Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China.,Key Laboratory of Obstetric & Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, China
| | - Fengyan Zhao
- Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China.,Key Laboratory of Obstetric & Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, China
| | - Junjie Ying
- Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China.,Key Laboratory of Obstetric & Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, China
| | - Yi Qu
- Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China.,Key Laboratory of Obstetric & Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, China
| | - Dezhi Mu
- Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China.,Key Laboratory of Obstetric & Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, China
| |
Collapse
|
7
|
Wu Y, Chen H, Ji Y, Na R, Mo Z, Ye D, Wang M, Qi J, Lin X, Ding Q, Xu J, Zheng SL, Sun Y, Meng W. Validation of the novel susceptibility loci for prostate cancer in a Chinese population. Oncol Lett 2017; 15:2567-2573. [PMID: 29434975 DOI: 10.3892/ol.2017.7602] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2017] [Accepted: 10/24/2017] [Indexed: 01/05/2023] Open
Abstract
The present study evaluated 23 newly identified susceptibility loci for prostate cancer (PCa) in a Chinese population and assessed whether any validated loci were associated with the genetic risk score (GRS) of PCa in a Chinese population. A total of 1,417 patients with PCa and 1,008 controls were recruited in the present study. The association of each single nucleotide polymorphism (SNP) with PCa risk and PCa aggressiveness was analyzed. The predictive ability of two GRSs based on 30 SNPs (GRS30) and the 9 most significant SNPs (GRS9) in the Chinese population were also compared. Among the 19 SNPs evaluated, 1 SNP (rs7153648 at 14q23) was associated with PCa risk [odds ratio (OR)=1.206, P<0.05)] and 1 SNP (rs636291 at 1p23) was associated with PCa aggressiveness (OR=1.123, P<0.05). GRS30 and GRS9 were significantly increased in patients with PCa compared with that among non-PCa controls. The areas under receiver operating characteristic curves of GRS9 and GRS 30 were similar (0.792 for GRS9 vs. 0.7994 for GRS30, P=0.138). To conclude, among the 19 SNPs evaluated, only 1 SNP was associated with PCa risk in the Chinese population. SNPs that were weakly associated with PCa were unlikely to improve the predictive ability of existing GRS in the Chinese population.
Collapse
Affiliation(s)
- Yishuo Wu
- Department of Urology, Huashan Hospital, Fudan University, Shanghai 200000, P.R. China.,Urology Research Center, Fudan University, Shanghai 200000, P.R. China
| | - Haitao Chen
- Center for Genomic Translational Medicine and Prevention, School of Public Health, Fudan University, Shanghai 200000, P.R. China
| | - Ying Ji
- Department of Urology, Huashan Hospital, Fudan University, Shanghai 200000, P.R. China
| | - Rong Na
- Department of Urology, Huashan Hospital, Fudan University, Shanghai 200000, P.R. China.,Urology Research Center, Fudan University, Shanghai 200000, P.R. China
| | - Zengnan Mo
- Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi 530000, P.R. China
| | - Dingwei Ye
- Department of Urology, Shanghai Cancer Center, Fudan University, Shanghai 200000, P.R. China
| | - Meilin Wang
- Department of Molecular and Genetic Toxicology, The Key Laboratory of Modern Toxicology of The Ministry of Education, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 210000, P.R. China
| | - Jun Qi
- Department of Urology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200000, P.R. China
| | - Xiaoling Lin
- Urology Research Center, Fudan University, Shanghai 200000, P.R. China.,Center for Genomic Translational Medicine and Prevention, School of Public Health, Fudan University, Shanghai 200000, P.R. China
| | - Qiang Ding
- Department of Urology, Huashan Hospital, Fudan University, Shanghai 200000, P.R. China.,Urology Research Center, Fudan University, Shanghai 200000, P.R. China
| | - Jianfeng Xu
- Urology Research Center, Fudan University, Shanghai 200000, P.R. China.,Program for Personalized Cancer Care, NorthShore University Health System, Evanston, IL 60201, USA
| | - S Lilly Zheng
- Program for Personalized Cancer Care, NorthShore University Health System, Evanston, IL 60201, USA
| | - Yinghao Sun
- Department of Urology, Changhai Hospital, The Second Military Medical University, Shanghai 200000, P.R. China
| | - Wei Meng
- Department of Epidemiology, School of Public Health, Fudan University, Shanghai 200000, P.R. China
| |
Collapse
|
8
|
Li R, Qin Z, Tang J, Han P, Xing Q, Wang F, Si S, Wu X, Tang M, Wang W, Zhang W. Association between 8q24 Gene Polymorphisms and the Risk of Prostate Cancer: A Systematic Review and Meta-Analysis. J Cancer 2017; 8:3198-3211. [PMID: 29158792 PMCID: PMC5665036 DOI: 10.7150/jca.20456] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2017] [Accepted: 08/07/2017] [Indexed: 12/22/2022] Open
Abstract
Though numerous studies have been conducted to investigate the associations between five 8q24 polymorphisms (rs6983267 T>G, rs1447295 C>A, rs16901979 C>A, rs6983561 A>C and rs10090154 C>T) and prostate cancer (PCa) risk, the available results remained contradictory. Therefore, we performed a comprehensive meta-analysis to derive a precise estimation of such associations. We searched electronic databases PubMed, EMBASE, Web of Science and Wan Fang for the relevant available studies up to February 1st, 2017, and 39 articles were ultimately adopted in this meta-analysis. All data were extracted independently by two investigators and recorded in a unified form. The strength of association between 8q24 polymorphisms and PCa susceptibility was evaluated by the pooled odds ratios (ORs) with 95% confidence intervals (CIs). Subgroup analysis was conducted based on ethnicity, source of controls and genotypic method. Overall, a total of 39 articles containing 80 studies were adopted in this meta-analysis. The results of this meta-analysis indicated that five 8q24 polymorphisms above were all related to PCa susceptibility. Besides, in the subgroup analysis by ethnicity, all selected 8q24 polymorphisms were significantly associated with PCa risk in Asian population. In addition, stratification analysis by source of controls showed that significant results were mostly concentrated in the studies' controls from general population. Moreover, when stratified by genotypic method, significant increased PCa risks were found by TaqMan method. Therefore, this meta-analysis demonstrated that 8q24 polymorphisms (rs6983267 T>G, rs1447295 C>A, rs16901979 C>A, rs6983561 A>C and rs10090154 C>T) were associated with the susceptibility to PCa, which held the potential biomarkers for PCa risk.
Collapse
Affiliation(s)
- Ran Li
- Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China
| | - Zhiqiang Qin
- Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China
| | - Jingyuan Tang
- Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China
| | - Peng Han
- Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China
| | - Qianwei Xing
- Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.,Department of Urology, Affiliated Hospital of Nantong University, Nantong, 226001, China
| | - Feng Wang
- Department of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China
| | - Shuhui Si
- Research Division of Clinical Pharmacology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China
| | - Xiaolu Wu
- Department of Pediatrics, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China
| | - Min Tang
- Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China
| | - Wei Wang
- Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China
| | - Wei Zhang
- Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China
| |
Collapse
|
9
|
Lin X, Chen Z, Gao P, Gao Z, Chen H, Qi J, Liu F, Ye D, Jiang H, Na R, Yu H, Shi R, Lu D, Zheng SL, Mo Z, Sun Y, Ding Q, Xu J. TEX15: A DNA repair gene associated with prostate cancer risk in Han Chinese. Prostate 2017; 77:1271-1278. [PMID: 28730685 DOI: 10.1002/pros.23387] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/13/2017] [Accepted: 06/22/2017] [Indexed: 11/12/2022]
Abstract
BACKGROUND Both common and rare genetic variants may contribute to risk of developing prostate cancer. Genome-wide association studies (GWASs) have identified ∼100 independent, common variants associated with prostate cancer risk. However, little is known about the association of rare variants (minor allele frequency [MAF] <1%) in the genome with prostate cancer risk. METHODS A two-stage study was used to test the association of rare, deleterious coding variants, annotated using predictive algorithms, with prostate cancer risk in Chinese men. Predicted rare, deleterious coding variants in the Illumina HumanExome-12 v1.1 beadchip were first evaluated in 1343 prostate cancer patients and 1008 controls. Significant variants were then validated in an additional 1816 prostate cancer patients and 1549 controls. RESULTS In the discovery stage, 14 predicted rare, deleterious coding variants were significantly associated with prostate cancer risk (P < 0.01). In the confirmation stage, Q1631H in TEX15 (rs142485241), a DNA repair gene, was significantly associated with prostate cancer risk (P = 0.0069). The estimated odds ratio (OR) of the variant in the combined analysis was 3.24 (95% Confidence Interval 1.85-6.06), P = 8.81 × 10-5 . Additionally, rs28756990 (V741F) at MLH3 (P = 0.06) and rs2961144 (I126V) at OR2A5 (P = 0.065) were marginally associated with prostate cancer risk in the replication stage. CONCLUSIONS Our study provided preliminary evidence that the rare variant Q1631H in DNA repair gene TEX15 is associated with prostate cancer risk. This finding complements known common prostate cancer risk-associated variants and suggests the possible role of DNA repair genes in prostate cancer development.
Collapse
Affiliation(s)
- Xiaoling Lin
- Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China
- Department of Urology, Huashan Hospital, Fudan University, Shanghai, China
- State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China
| | - Zhongzhong Chen
- State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China
| | - Peng Gao
- Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China
- Department of Urology, Huashan Hospital, Fudan University, Shanghai, China
| | - Zhimei Gao
- Central Laboratory, Shanghai Children's Hospital, Shanghai Jiaotong University, Shanghai, China
| | - Haitao Chen
- Center for Genomic Translational Medicine and Prevention, School of Public Health, Fudan University, Shanghai, China
| | - Jun Qi
- Department of Urology, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
| | - Fang Liu
- Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China
- Department of Urology, Huashan Hospital, Fudan University, Shanghai, China
| | - Dingwei Ye
- Department of Urology, Fudan University Shanghai Cancer Center and Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
| | - Haowen Jiang
- Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China
- Department of Urology, Huashan Hospital, Fudan University, Shanghai, China
| | - Rong Na
- Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China
- Department of Urology, Huashan Hospital, Fudan University, Shanghai, China
| | - Hongjie Yu
- State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China
| | - Rong Shi
- School of Public Health, Shanghai Jiaotong University, Shanghai, China
| | - Daru Lu
- State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China
| | - Siqun Lilly Zheng
- Program for Personalized Cancer Care, NorthShore University HealthSystem, Evanston, Illinois
| | - Zengnan Mo
- Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China
- Department of Urology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China
| | - Yinghao Sun
- Department of Urology, Shanghai Changhai Hospital, The Second Military Medical University, Shanghai, China
| | - Qiang Ding
- Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China
- Department of Urology, Huashan Hospital, Fudan University, Shanghai, China
| | - Jianfeng Xu
- Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China
- Department of Urology, Huashan Hospital, Fudan University, Shanghai, China
| |
Collapse
|
10
|
Decreased gene expression of CD2AP in Chinese patients with sporadic Alzheimer's disease. Neurobiol Aging 2017; 56:212.e5-212.e10. [DOI: 10.1016/j.neurobiolaging.2017.03.013] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2016] [Revised: 01/23/2017] [Accepted: 03/08/2017] [Indexed: 01/07/2023]
|
11
|
Jiang X, Zhang M, Bai XY, Li S, Wu H. Association between 17q25.3-rs6465657 polymorphism and prostate cancer susceptibility: a meta-analysis based on 19 studies. Onco Targets Ther 2016; 9:4491-503. [PMID: 27524905 PMCID: PMC4966688 DOI: 10.2147/ott.s104775] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Background Genome-wide association studies have identified rs6465657 polymorphism at chromosome 17q25.3 as a new prostate cancer (PCa) susceptibility locus in people of European descent. However, subsequent replication studies have yielded inconsistent results among different ethnicities. In this study, a comprehensive meta-analysis was conducted to systematically evaluate the relationship between rs6465657 polymorphism and PCa risk. Methods All the articles involved were identified from PubMed, EMBASE, Web of Science, EBSCO databases, and Google Scholar before December 2015. The odds ratios (ORs) with corresponding 95% confidence internals (95% CIs) were pooled under the allele model. Fourteen eligible articles with 19 studies were finally included. Results In the overall population, the 17q25.3-rs6465657C allele was found to be significantly associated with increased risk of PCa compared to the T allele (OR =1.097; 95% CI: 1.061–1.134; P<0.001). In the subgroup analysis stratified by ethnicity, significantly increased risk was found in the Caucasian population (OR =1.120; 95% CI: 1.078–1.162; P<0.001), while the difference of OR did not reach the statistical significance in the Asian or African-American population. The analyses of sensitivity indicated the robust stability of the results, and the Begg’s and Egger’s test indicated that no publication bias existed. Conclusion The current meta-analysis suggested that the 17q25.3-rs6465657 polymorphism could be associated with PCa susceptibility, especially in the Caucasians, while this association might be different in other ethnicities.
Collapse
Affiliation(s)
- Xiao Jiang
- Laboratory of Molecular Medicine & Pharmacy, School of Life Science and Biotechnology, Dalian University of Technology, Dalian, People's Republic of China; Department of Gastroenterology, Dalian Municipal Central Hospital Affiliated of Dalian Medical University, Dalian, People's Republic of China
| | - Mei Zhang
- Department of Biochemistry and Molecular Biology, Heilongjiang University of Chinese Medicine, Haerbin, People's Republic of China
| | - Xiao-Yan Bai
- Laboratory of Molecular Medicine & Pharmacy, School of Life Science and Biotechnology, Dalian University of Technology, Dalian, People's Republic of China
| | - Shujing Li
- Laboratory of Molecular Medicine & Pharmacy, School of Life Science and Biotechnology, Dalian University of Technology, Dalian, People's Republic of China
| | - Huijian Wu
- Laboratory of Molecular Medicine & Pharmacy, School of Life Science and Biotechnology, Dalian University of Technology, Dalian, People's Republic of China
| |
Collapse
|
12
|
Zhu Y, Wang HK, Qu YY, Ye DW. Prostate cancer in East Asia: evolving trend over the last decade. Asian J Androl 2016; 17:48-57. [PMID: 25080928 PMCID: PMC4291877 DOI: 10.4103/1008-682x.132780] [Citation(s) in RCA: 77] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
Prostate cancer is now becoming an emerging health priority in East Asia. Most of our current knowledge on Prostate cancer has been generated from studies conducted in Western population; however, there is considerable heterogeneity of Prostate cancer between East and West. In this article, we reviewed epidemiologic trends, risk factors, disease characteristics and management of Prostate cancer in East Asian population over the last decade. Growing evidence from East Asia suggests an important role of genetic and environmental risk factors interactions in the carcinogenesis of Prostate cancer. Exposure to westernized diet and life style and improvement in health care in combination contribute substantially to the increasing epidemic in this region. Diagnostic and treatment guidelines in East Asia are largely based on Western knowledge. Although there is a remarkable improvement in the outcome over the last decade, ample evidence suggests an inneglectable difference in diagnostic accuracy, treatment efficacy and adverse events between different populations. The knowledge from western countries should be calibrated in the Asian setting to provide a better race-based treatment approach. In this review, we intend to reveal the evolving trend of Prostate cancer in the last decade, in order to gain evidence to improve Prostate cancer prevention and control in East Asia.
Collapse
Affiliation(s)
| | | | | | - Ding-Wei Ye
- Department of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Fudan University Shanghai Medical College, Shanghai 200032, China
| |
Collapse
|
13
|
Wei HM, Chen HT, Wang P, Wu YS, Na R, Liu F, Sun JS, Jiang DK, Lu DR, Xu J. Prostate cancer antigen 3 and genetic risk score as markers for the detection of prostate cancer in the Chinese population. Asian J Androl 2016; 17:168-70. [PMID: 25412674 PMCID: PMC4291867 DOI: 10.4103/1008-682x.143245] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Affiliation(s)
| | | | | | | | | | | | | | | | | | - Jianfeng Xu
- State Key Laboratory of Genetic Engineering; Center for Genetic Epidemiology, School of Life Sciences, Fudan University, Shanghai 200433; Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai 200040, China; Center for Cancer Genomics, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA,
| |
Collapse
|
14
|
Monn MF, Tatem AJ, Cheng L. Prevalence and management of prostate cancer among East Asian men: Current trends and future perspectives. Urol Oncol 2015; 34:58.e1-9. [PMID: 26493449 DOI: 10.1016/j.urolonc.2015.09.003] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2015] [Revised: 09/08/2015] [Accepted: 09/11/2015] [Indexed: 12/21/2022]
Abstract
OBJECTIVES Previously East Asian men had been considered less likely to develop or die of prostate cancer. Emerging research and the onset of prostate-specific antigen screening in East Asian countries suggests that this may not be the case. We sought to analyze epidemiology and molecular genetic data and recent trends in the management of prostate cancer among East Asian men. METHODS AND MATERIALS We performed literature searches using PubMed, Embase, and Google Scholar to examine current literature on prostate cancer in East Asian men. Additionally, articles were searched for further references related to the topic. RESULTS Recent studies have reported increasing incidence of prostate cancer identified in East Asian men. Prostate cancer mortality has increased and is currently the fourth leading cause of death among men in Shanghai, China. Although prostate cancer was considered less aggressive among East Asian men, studies suggest that it is similarly aggressive to prostate cancer in Western populations. Molecular markers such as the TEMPRESS:ERG fusion gene and PTEN loss may provide novel methods of screening East Asian men for prostate cancer. National-level guidelines for prostate cancer screening and management are only available in Japan. CONCLUSIONS The prevalence of prostate cancer in East Asian men is likely similar to that in Western male populations. East Asian men present at higher stages of prostate cancer, likely because of a lack of standardized screening protocols. Urologists in Western countries should screen East Asian men for prostate cancer using the same standards as used for Western men.
Collapse
Affiliation(s)
- M Francesca Monn
- Department of Urology, Indiana University School of Medicine, Indianapolis, IN
| | - Alexander J Tatem
- Department of Urology, Indiana University School of Medicine, Indianapolis, IN
| | - Liang Cheng
- Department of Urology, Indiana University School of Medicine, Indianapolis, IN; Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN.
| |
Collapse
|
15
|
Zhang GM, Zhu Y, Chen HT, Han CT, Liu F, Xu JF, Ye DW. Association Between the Body Mass Index and Prostate Cancer at Biopsy is Modified by Genetic Risk: A Cross-Sectional Analysis in China. Medicine (Baltimore) 2015; 94:e1603. [PMID: 26496266 PMCID: PMC4620779 DOI: 10.1097/md.0000000000001603] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
Herein, we aimed to examine whether the association of body mass index (BMI) with prostate cancer (PCa) at biopsy differs according to genetic susceptibility.In a multicenter prospective cohort including 1120 men undergoing diagnostic prostate biopsy in China, we evaluated the interaction between BMI and genetic risk score (GRS) comprising 24 PCa-associated single nucleotide polymorphisms (SNPs), as well as a GRS consisting of 7 SNPs derived from an East-Asian population. The genetic risk was defined as low, intermediate, or high when GRS fell in the first, second, and third tertiles, respectively.We observed a significant interaction between BMI and PCa GRS (Pinteraction = 0.047), suggesting that the predictive value of BMI on PCa was strongly modified by genetic susceptibility. In men with high genetic risk, BMI was an independent predictor of PCa (odds ratio [OR] = 1.167, P = 0.008) after adjusting for conventional risk factors. The relationship between BMI and PCa risk diminished (P = 0.990) in men with low genetic risk. The interaction was more pronounced with the East-Asian GRS (Pinteraction = 0.032), suggesting that the overall GRS interaction most likely occurs through genetic susceptibility in the East-Asian population.Our results suggest that the predictive effect of BMI on the PCa risk is strongly modified by individual genetic susceptibility. The association is more positive among men with high genetic risk for PCa.
Collapse
Affiliation(s)
- Gui-Ming Zhang
- From the Department of Urology, Fudan University Shanghai Cancer Center, People's Republic of China (GMZ, YZ, CTH, DWY); Department of Oncology, Shanghai Medical Colleague, Fudan University, People's Republic of China (GMZ, YZ, CTH, DWY); Fudan Institute of Urology, Huashan Hospital, Fudan University, People's Republic of China (HTC, FL, JFX); State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, People's Republic of China (HTC, FL, JFX); Center for Genetic Epidemiology, School of Life Sciences, Fudan University, People's Republic of China (HTC, FL, JFX); and Center for Cancer Genomics, Wake Forest School of Medicine, Winston-Salem, NC (JFX)
| | | | | | | | | | | | | |
Collapse
|
16
|
Abstract
PURPOSE OF REVIEW Recent advances in sequencing technologies have allowed for the identification of genetic variants within germline DNA that can explain a significant portion of the genetic underpinnings of prostate cancer. Despite evidence suggesting that these genetic variants can be used for improved risk stratification, they have not yet been routinely incorporated into routine clinical practice. This review highlights their potential utility in prostate cancer screening. RECENT FINDINGS There are now almost 100 genetic variants, called single nucleotide polymorphisms (SNPs) that have been recently found to be associated with the risk of developing prostate cancer. In addition, some of these prostate cancer risk SNPs have also been found to influence prostate specific antigen (PSA) expression levels and potentially aggressive disease. SUMMARY Incorporation of panels of prostate cancer risk SNPs into clinical practice offers potential to provide improvements in patient selection for prostate cancer screening; PSA interpretation (e.g. by correcting for the presence of SNPs that influence PSA expression levels; decision for biopsy (using prostate cancer risk SNPs); and possibly the decision for treatment. A proposed clinical algorithm incorporating these prostate cancer risk SNPs is discussed.
Collapse
|
17
|
Ao X, Liu Y, Bai XY, Qu X, Xu Z, Hu G, Chen M, Wu H. Association between EHBP1 rs721048(A>G) polymorphism and prostate cancer susceptibility: a meta-analysis of 17 studies involving 150,678 subjects. Onco Targets Ther 2015; 8:1671-80. [PMID: 26185455 PMCID: PMC4500625 DOI: 10.2147/ott.s84034] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
Background EHBP1 rs721048(A) was first identified as a prostate cancer (PCa) risk in Caucasians by genome-wide association study, but subsequent replication studies involving Caucasian and other ethnicities did not produce consistent results. The aim of this study was to obtain a more definite association between rs721048(A) and PCa risk. Methods We comprehensively searched several databases updated to September 2014, including PubMed, Web of Science, EBSCO, and Google Scholar. Two authors independently screened and reviewed the eligibility of each study. The quality of the included studies was assessed by the Newcastle–Ottawa scale. The association of rs721048(A) and PCa risk was assessed by pooling odds ratios (ORs) with 95% confidence intervals (CIs). Results A total of 17 studies, including 48,135 cases and 102,543 controls, published between 2008 and 2014 were included in the meta-analysis. Overall, the pooled analysis demonstrated that rs721048(A) was significantly associated with the risk of PCa under the allele model (OR=1.14, 95% CI=1.11–1.17, P=0.000). Subgroup analysis based on ethnicity revealed a significant association between rs721048(A) and PCa in Caucasian (OR=1.14, 95% CI=1.11–1.16, P=0.000), African descent (OR=1.11, 95% CI=1.01–1.23, P=0.025), and Asian (OR=1.35, 95% CI=1.12–1.64, P=0.002). Conclusion Our results provided strong evidence that rs721048(A) could be a risk factor for PCa.
Collapse
Affiliation(s)
- Xiang Ao
- Laboratory of Molecular Medicine & Pharmacy, School of Life Science and Biotechnology, Dalian University of Technology, Dalian, People's Republic of China
| | - Ying Liu
- Laboratory of Molecular Medicine & Pharmacy, School of Life Science and Biotechnology, Dalian University of Technology, Dalian, People's Republic of China
| | - Xiao-Yan Bai
- Laboratory of Molecular Medicine & Pharmacy, School of Life Science and Biotechnology, Dalian University of Technology, Dalian, People's Republic of China
| | - Xinjian Qu
- Laboratory of Molecular Medicine & Pharmacy, School of Life Science and Medicine, Dalian University of Technology, Panjin, Liaoning, People's Republic of China
| | - Zhaowei Xu
- Laboratory of Molecular Medicine & Pharmacy, School of Life Science and Biotechnology, Dalian University of Technology, Dalian, People's Republic of China
| | - Gaolei Hu
- Laboratory of Molecular Medicine & Pharmacy, School of Life Science and Biotechnology, Dalian University of Technology, Dalian, People's Republic of China
| | - Min Chen
- Laboratory of Molecular Medicine & Pharmacy, School of Life Science and Biotechnology, Dalian University of Technology, Dalian, People's Republic of China
| | - Huijian Wu
- Laboratory of Molecular Medicine & Pharmacy, School of Life Science and Biotechnology, Dalian University of Technology, Dalian, People's Republic of China ; Laboratory of Molecular Medicine & Pharmacy, School of Life Science and Medicine, Dalian University of Technology, Panjin, Liaoning, People's Republic of China
| |
Collapse
|
18
|
Zhao CX, Liu M, Xu Y, Yang K, Wei D, Shi XH, Yang F, Zhang YG, Wang X, Liang SY, Zhao F, Zhang YR, Wang NN, Chen X, Sun L, Zhu XQ, Yuan HP, Zhu L, Yang YG, Tang L, Jiao HY, Huo ZH, Wang JY, Yang Z. 8q24 rs4242382 polymorphism is a risk factor for prostate cancer among multi-ethnic populations: evidence from clinical detection in China and a meta-analysis. Asian Pac J Cancer Prev 2015; 15:8311-7. [PMID: 25339022 DOI: 10.7314/apjcp.2014.15.19.8311] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Evidence supporting an association between the 8q24 rs4242382-A polymorphism and prostate cancer (PCa) risk has been reported in North American and Europe populations, though data from Asian populations remain limited. We therefore investigated this association by clinical detection in China, and meta-analysis in Asian, Caucasian and African-American populations. MATERIALS AND METHODS Blood samples and clinical information were collected from ethnically Chinese men from Northern China with histologically- confirmed PCa (n=335) and from age-matched normal controls (n=347). The 8q24 (rs4242382) gene polymorphism was genotyped by polymerase chain reaction-high-resolution melting analysis. We initially analyzed the associations between the risk allele and PCa and clinical covariates. A meta-analysis was then performed using genotyping data from a total of 1,793 PCa cases and 1,864 controls from our study and previously published studies in American and European populations, to determine the association between PCa and risk genotype. RESULTS The incidence of the risk allele was higher in PCa cases than controls (0.222 vs 0.140, P=7.3?10-5), suggesting that the 8q24 rs4242382-A polymorphism was associated with PCa risk in Chinese men. The genotypes in subjects were in accordance with a dominant genetic model (ORadj=2.03, 95%CI: 1.42-2.91, Padj=1.1?10-4). Presence of the risk allele rs4242382-A at 8q24 was also associated with clinical covariates including age at diagnosis ≥65 years, prostate specific antigen >10 ng/ml, Gleason score <8, tumor stage and aggressive PCa, compared with the non-risk genotype (P=4.6?10-5-3.0?10-2). Meta-analysis confirmed the association between 8q24 rs4242382-A polymorphism and PCa risk (OR=1.62, 95%CI: 1.39-1.88, P=1.0?10-5) across Asian, Caucasian and African American populations. CONCLUSIONS The replicated data suggest that the 8q24 rs4242382-A variation might be associated with increased PCa susceptibility in Asian, Caucasian and African American populations. These results imply that this polymorphism may be a useful risk biomarker for PCa in multi-ethnic populations.
Collapse
Affiliation(s)
- Cheng-Xiao Zhao
- The Key Laboratory of Geriatrics, Beijing Hospital and Beijing Institute of Geriatrics, Chinese Ministry of Health, Beijing, China E-mail : ,
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Virlogeux V, Graff RE, Hoffmann TJ, Witte JS. Replication and heritability of prostate cancer risk variants: impact of population-specific factors. Cancer Epidemiol Biomarkers Prev 2015; 24:938-43. [PMID: 25809866 DOI: 10.1158/1055-9965.epi-14-1372] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2014] [Accepted: 03/13/2015] [Indexed: 11/16/2022] Open
Abstract
BACKGROUND Prostate cancer incidence and mortality rates vary across populations, with African American men exhibiting the highest rates. To date, genome-wide association studies have identified 104 SNPs independently associated with prostate cancer in men of European ancestry. METHODS We investigated whether the ability to replicate findings for these 104 SNPs in African American, Asian, and Latino populations depends on variation in risk allele frequencies (RAF), strength of associations, and/or patterns of linkage disequilibrium (LD) at the associated loci. We extracted estimates of effect from the literature, and determined RAF and LD information across the populations from the 1000 Genomes Project. RESULTS Risk variants were largely replicated across populations. Relative to Europeans, 83% had smaller effect sizes among African Americans and 73% demonstrated smaller effect sizes among Latinos. Among Asians, however, 56% showed larger effect sizes than among Europeans. The largest difference in RAFs was observed between European and African ancestry populations, but this difference did not impact our ability to replicate. The extent of LD within 250 kb of risk loci in Asian ancestry populations was suggestively lower for variants that did not replicate (P = 0.013). CONCLUSIONS Despite substantial overlap in prostate cancer risk SNPs across populations, the variation in prostate cancer incidence among different populations may still in part reflect unique underlying genetic architectures. IMPACT Studying different ancestral populations is crucial for deciphering the genetic basis of prostate cancer.
Collapse
Affiliation(s)
- Victor Virlogeux
- Department of Epidemiology and Biostatistics, University of California, San Francisco, California. Department of Biology, Ecole Normale Supérieure de Lyon, Lyon, France
| | - Rebecca E Graff
- Department of Epidemiology and Biostatistics, University of California, San Francisco, California
| | - Thomas J Hoffmann
- Department of Epidemiology and Biostatistics, University of California, San Francisco, California. Institute for Human Genetics, University of California, San Francisco, California
| | - John S Witte
- Department of Epidemiology and Biostatistics, University of California, San Francisco, California. Institute for Human Genetics, University of California, San Francisco, California. Department of Urology, University of California, San Francisco, California. UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California.
| |
Collapse
|
20
|
Li W, Gu M. NUDT11 rs5945572 polymorphism and prostate cancer risk: a meta-analysis. Int J Clin Exp Med 2015; 8:3474-3481. [PMID: 26064238 PMCID: PMC4443072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2014] [Accepted: 02/03/2015] [Indexed: 06/04/2023]
Abstract
The association between the NUDT10 rs5945572 polymorphism and prostate cancer (PCa) was not clear. We thus conducted a meta-analysis to assess the association between NUDT10 rs5945572 polymorphism and PCa risk. A literature search was carried out using PUBMED, EMBASE, and Cochrane Library Central database before Dec 2014. The strength of the associations between the NUDT10 rs5945572 polymorphism and PCa risk was measured by odds ratios (OR) with 95% confidence intervals (CI). The random-effects model was used. NUDT10 rs5945572 polymorphism was significantly associated with PCa risk (OR = 1.22, 95% CI 1.19-1.26, P < 0.001, I(2) = 0%, Figure 2). In the subgroup analysis by ethnicity, a significant association was found among Caucasians (OR = 1.25, 95% CI 1.00-1.57, P = 0.05, I(2) = 0%), and Asians (OR = 1.23, 95% CI 1.19-1.28, P < 0.001, I(2) = 0%), and Africans (OR = 1.22, 95% CI 1.03-1.45, P = 0.02, I(2) = 48%). In conclusion, this meta-analysis found a significant association between NUDT10 rs5945572 polymorphism and prostate cancer.
Collapse
Affiliation(s)
- Wencheng Li
- Department of Urology, Nanjing First Hospital, Nanjing Medical UniversityNanjing 210006, Jiangsu, China
| | - Min Gu
- Department of Urology, The First Affiliated Hospital of Nanjing Medical UniversityNanjing 210029, Jiangsu, China
| |
Collapse
|
21
|
Painter JN, O'Mara TA, Batra J, Cheng T, Lose FA, Dennis J, Michailidou K, Tyrer JP, Ahmed S, Ferguson K, Healey CS, Kaufmann S, Hillman KM, Walpole C, Moya L, Pollock P, Jones A, Howarth K, Martin L, Gorman M, Hodgson S, De Polanco MME, Sans M, Carracedo A, Castellvi-Bel S, Rojas-Martinez A, Santos E, Teixeira MR, Carvajal-Carmona L, Shu XO, Long J, Zheng W, Xiang YB, Montgomery GW, Webb PM, Scott RJ, McEvoy M, Attia J, Holliday E, Martin NG, Nyholt DR, Henders AK, Fasching PA, Hein A, Beckmann MW, Renner SP, Dörk T, Hillemanns P, Dürst M, Runnebaum I, Lambrechts D, Coenegrachts L, Schrauwen S, Amant F, Winterhoff B, Dowdy SC, Goode EL, Teoman A, Salvesen HB, Trovik J, Njolstad TS, Werner HMJ, Ashton K, Proietto T, Otton G, Tzortzatos G, Mints M, Tham E, Hall P, Czene K, Liu J, Li J, Hopper JL, Southey MC, Ekici AB, Ruebner M, Johnson N, Peto J, Burwinkel B, Marme F, Brenner H, Dieffenbach AK, Meindl A, Brauch H, Lindblom A, Depreeuw J, Moisse M, Chang-Claude J, Rudolph A, Couch FJ, Olson JE, Giles GG, Bruinsma F, Cunningham JM, Fridley BL, Børresen-Dale AL, Kristensen VN, Cox A, Swerdlow AJ, Orr N, Bolla MK, Wang Q, Weber RP, Chen Z, Shah M, French JD, Pharoah PDP, Dunning AM, Tomlinson I, Easton DF, Edwards SL, Thompson DJ, Spurdle AB. Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk. Hum Mol Genet 2015; 24:1478-92. [PMID: 25378557 PMCID: PMC4321445 DOI: 10.1093/hmg/ddu552] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2014] [Revised: 10/13/2014] [Accepted: 10/24/2014] [Indexed: 12/14/2022] Open
Abstract
Common variants in the hepatocyte nuclear factor 1 homeobox B (HNF1B) gene are associated with the risk of Type II diabetes and multiple cancers. Evidence to date indicates that cancer risk may be mediated via genetic or epigenetic effects on HNF1B gene expression. We previously found single-nucleotide polymorphisms (SNPs) at the HNF1B locus to be associated with endometrial cancer, and now report extensive fine-mapping and in silico and laboratory analyses of this locus. Analysis of 1184 genotyped and imputed SNPs in 6608 Caucasian cases and 37 925 controls, and 895 Asian cases and 1968 controls, revealed the best signal of association for SNP rs11263763 (P = 8.4 × 10(-14), odds ratio = 0.86, 95% confidence interval = 0.82-0.89), located within HNF1B intron 1. Haplotype analysis and conditional analyses provide no evidence of further independent endometrial cancer risk variants at this locus. SNP rs11263763 genotype was associated with HNF1B mRNA expression but not with HNF1B methylation in endometrial tumor samples from The Cancer Genome Atlas. Genetic analyses prioritized rs11263763 and four other SNPs in high-to-moderate linkage disequilibrium as the most likely causal SNPs. Three of these SNPs map to the extended HNF1B promoter based on chromatin marks extending from the minimal promoter region. Reporter assays demonstrated that this extended region reduces activity in combination with the minimal HNF1B promoter, and that the minor alleles of rs11263763 or rs8064454 are associated with decreased HNF1B promoter activity. Our findings provide evidence for a single signal associated with endometrial cancer risk at the HNF1B locus, and that risk is likely mediated via altered HNF1B gene expression.
Collapse
Affiliation(s)
- Jodie N Painter
- QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
| | - Tracy A O'Mara
- QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
| | - Jyotsna Batra
- Australian Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation, and School of Biomedical Science and
| | - Timothy Cheng
- Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
| | - Felicity A Lose
- QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
| | - Joe Dennis
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care and
| | - Kyriaki Michailidou
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care and
| | - Jonathan P Tyrer
- Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK
| | - Shahana Ahmed
- Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK
| | - Kaltin Ferguson
- QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
| | - Catherine S Healey
- Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK
| | - Susanne Kaufmann
- QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
| | | | - Carina Walpole
- Australian Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation, and School of Biomedical Science and
| | - Leire Moya
- Australian Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation, and School of Biomedical Science and
| | - Pamela Pollock
- Institute of Health and Biomedical Innovation and School of Biomedical Science, Queensland University of Technology, Brisbane, QLD, Australia
| | - Angela Jones
- Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
| | - Kimberley Howarth
- Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
| | - Lynn Martin
- Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
| | - Maggie Gorman
- Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
| | - Shirley Hodgson
- Department of Clinical Genetics, St George's Hospital Medical School, London, UK
| | | | - Monica Sans
- Department of Biological Anthropology, College of Humanities and Educational Sciences, University of the Republic, Magallanes, Montevideo, Uruguay
| | - Angel Carracedo
- Grupo de Medicina Xenómica, Fundación Galega de Medicina Xenómica (SERGAS) and CIBERER, Universidade de Santiago de Compostela, Santiago de Compostela, Spain, Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, KSA
| | - Sergi Castellvi-Bel
- Genetic Predisposition to Colorectal Cancer Group, Gastrointestinal & Pancreatic Oncology Team, IDIBAPS/CIBERehd/Hospital Clínic, Centre Esther Koplowitz (CEK), Barcelona, Spain
| | - Augusto Rojas-Martinez
- Universidad Autónoma de Nuevo León, Pedro de Alba s/n, San Nicolás de Los Garza, Nuevo León, Mexico
| | | | - Manuel R Teixeira
- Department of Genetics, Portuguese Oncology Institute, Porto, Portugal, Biomedical Sciences Institute (ICBAS), University of Porto, Porto, Portugal
| | - Luis Carvajal-Carmona
- Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK, Grupo de Investigación Citogenética, Filogenia y Evolución de Poblaciones, Universidad del Tolima, Ibagué, Tolima, Colombia, Genome Center and Department of Biochemistry and Molecular Medicine, University of California, Davis, CA, USA
| | - Xiao-Ou Shu
- Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Jirong Long
- Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Wei Zheng
- Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Yong-Bing Xiang
- Department of Epidemiology, Shanghai Cancer Institute, Shanghai, China
| | | | - Penelope M Webb
- QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
| | - Rodney J Scott
- Hunter Medical Research Institute and, Hunter Area Pathology Service, John Hunter Hospital, Newcastle, NSW, Australia, Centre for Information Based Medicine and School of Biomedical Science and Pharmacy
| | - Mark McEvoy
- Centre for Clinical Epidemiology and Biostatistics, School of Medicine and Public Health
| | - John Attia
- Hunter Medical Research Institute and, Centre for Clinical Epidemiology and Biostatistics, School of Medicine and Public Health
| | - Elizabeth Holliday
- Hunter Medical Research Institute and, Centre for Information Based Medicine and School of Medicine and Public Health
| | | | - Dale R Nyholt
- QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
| | - Anjali K Henders
- QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
| | - Peter A Fasching
- Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - Alexander Hein
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - Matthias W Beckmann
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - Stefan P Renner
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | | | - Peter Hillemanns
- Clinics of Gynaecology and Obstetrics, Hannover Medical School, Hannover, Germany
| | - Matthias Dürst
- Dept. of Gynaecology, Friedrich Schiller University Jena, Jena, Germany
| | - Ingo Runnebaum
- Dept. of Gynaecology, Friedrich Schiller University Jena, Jena, Germany
| | - Diether Lambrechts
- Vesalius Research Center, VIB, Leuven, Belgium, Department of Oncology, Laboratory for Translational Genetics
| | - Lieve Coenegrachts
- Division of Gynaecological Oncology, Department of Oncology, University Hospital Leuven, KU Leuven, Belgium
| | - Stefanie Schrauwen
- Division of Gynaecological Oncology, Department of Oncology, University Hospital Leuven, KU Leuven, Belgium
| | - Frederic Amant
- Division of Gynaecological Oncology, Department of Oncology, University Hospital Leuven, KU Leuven, Belgium
| | - Boris Winterhoff
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology
| | - Sean C Dowdy
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology
| | - Ellen L Goode
- Division of Epidemiology, Department of Health Science Research and
| | - Attila Teoman
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology
| | - Helga B Salvesen
- Department of Clinical Science, Centre for Cancerbiomarkers, The University of Bergen, Norway, Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway
| | - Jone Trovik
- Department of Clinical Science, Centre for Cancerbiomarkers, The University of Bergen, Norway, Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway
| | - Tormund S Njolstad
- Department of Clinical Science, Centre for Cancerbiomarkers, The University of Bergen, Norway, Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway
| | - Henrica M J Werner
- Department of Clinical Science, Centre for Cancerbiomarkers, The University of Bergen, Norway, Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway
| | - Katie Ashton
- Hunter Area Pathology Service, John Hunter Hospital, Newcastle, NSW, Australia, Faculty of Health, Centre for Information Based Medicine and the Discipline of Medical Genetics, School of Biomedical Sciences and Pharmacy and
| | - Tony Proietto
- Faculty of Health, School of Medicine and Public Health, University of Newcastle, NSW, Australia
| | - Geoffrey Otton
- Faculty of Health, School of Medicine and Public Health, University of Newcastle, NSW, Australia
| | | | | | - Emma Tham
- Department of Molecular Medicine and Surgery and
| | - Per Hall
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - Kamila Czene
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - Jianjun Liu
- Human Genetics, Genome Institute of Singapore, Singapore
| | - Jingmei Li
- Human Genetics, Genome Institute of Singapore, Singapore
| | - John L Hopper
- Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health and
| | - Melissa C Southey
- Department of Pathology, Genetic Epidemiology Laboratory, The University of Melbourne, Melbourne, VIC, Australia
| | - Arif B Ekici
- Institute of Human Genetics, University Hospital, Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - Matthias Ruebner
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | | | - Julian Peto
- London School of Hygiene and Tropical Medicine, London, UK
| | - Barbara Burwinkel
- Molecular Biology of Breast Cancer, Department of Gynecology and Obstetrics, Molecular Epidemiology, C080
| | - Frederik Marme
- Molecular Biology of Breast Cancer, Department of Gynecology and Obstetrics, National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany
| | - Hermann Brenner
- Division of Clinical Epidemiology and Aging Research, German Cancer Consortium (DKTK), Heidelberg, Germany
| | - Aida K Dieffenbach
- Division of Clinical Epidemiology and Aging Research, German Cancer Consortium (DKTK), Heidelberg, Germany
| | - Alfons Meindl
- Division of Tumor Genetics, Department of Obstetrics and Gynecology, Technical University of Munich, Munich, Germany
| | - Hiltrud Brauch
- Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology Stuttgart, University of Tuebingen, Germany
| | | | | | | | - Jenny Chang-Claude
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Anja Rudolph
- Department of Cancer Epidemiology/Clinical Cancer Registry and Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg, Germany
| | - Fergus J Couch
- Departments of Laboratory Medicine and Pathology, and Health Science Research, Mayo Clinic, Rochester, MN, USA
| | - Janet E Olson
- Division of Epidemiology, Department of Health Science Research and
| | - Graham G Giles
- Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health and Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, VIC, Australia, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC, Australia
| | - Fiona Bruinsma
- Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, VIC, Australia
| | - Julie M Cunningham
- Departments of Laboratory Medicine and Pathology, and Health Science Research, Mayo Clinic, Rochester, MN, USA
| | - Brooke L Fridley
- Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS, USA
| | - Anne-Lise Børresen-Dale
- Department of Genetics, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo, Norway, Faculty of Medicine, The K.G. Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, University of Oslo, Oslo, Norway
| | - Vessela N Kristensen
- Department of Genetics, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo, Norway, Faculty of Medicine, The K.G. Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, University of Oslo, Oslo, Norway, Division of Medicine, Department of Clinical Molecular Oncology, Akershus University Hospital, Ahus, Norway
| | - Angela Cox
- Department of Oncology, Sheffield Cancer Research Centre, University of Sheffield, Sheffield, UK
| | - Anthony J Swerdlow
- Division of Genetics and Epidemiology and, Division of Breast Cancer Research, Institute of Cancer Research, London, UK
| | - Nicholas Orr
- Division of Breast Cancer Research, Institute of Cancer Research, London, UK
| | - Manjeet K Bolla
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care and
| | - Qin Wang
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care and
| | - Rachel Palmieri Weber
- Department of Community and Family Medicine, Duke University School of Medicine, Durham, NC, USA
| | - Zhihua Chen
- Division of Population Sciences, Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA
| | - Mitul Shah
- Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK
| | - Juliet D French
- QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
| | - Paul D P Pharoah
- Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK
| | - Alison M Dunning
- Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK
| | - Ian Tomlinson
- Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
| | - Douglas F Easton
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care and Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK
| | - Stacey L Edwards
- QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
| | - Deborah J Thompson
- Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK
| | - Amanda B Spurdle
- QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia,
| |
Collapse
|
22
|
An expressed retrogene of the master embryonic stem cell gene POU5F1 is associated with prostate cancer susceptibility. Am J Hum Genet 2014; 94:395-404. [PMID: 24581739 DOI: 10.1016/j.ajhg.2014.01.019] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2013] [Accepted: 01/31/2014] [Indexed: 12/21/2022] Open
Abstract
Genetic association studies of prostate and other cancers have identified a major risk locus at chromosome 8q24. Several independent risk variants at this locus alter transcriptional regulatory elements, but an affected gene and mechanism for cancer predisposition have remained elusive. The retrogene POU5F1B within the locus has a preserved open reading frame encoding a homolog of the master embryonic stem cell transcription factor Oct4. We find that 8q24 risk alleles are expression quantitative trait loci correlated with reduced expression of POU5F1B in prostate tissue and that predicted deleterious POU5F1B missense variants are also associated with risk of transformation. POU5F1 is known to be self-regulated by the encoded Oct4 transcription factor. We further observe that POU5F1 expression is directly correlated with POU5F1B expression. Our results suggest that a pathway critical to self-renewal of embryonic stem cells may also have a role in the origin of cancer.
Collapse
|
23
|
Zhao F, Xu Y, Yang K, Liu M, Wei D, Zhang Y, Shi X, Yang F, Wang X, Liang S, Zhao C, Chen X, Sun L, Zhu X, Wang N, Hui J, Zhang Y, Zhu L, Yang Y, Tang L, Wang J, Yang Z. THADA gene polymorphism and prostate cancer risk: a meta-analysis. Oncol Res Treat 2014; 37:106-10. [PMID: 24685913 DOI: 10.1159/000360206] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2013] [Accepted: 01/29/2014] [Indexed: 11/19/2022]
Abstract
BACKGROUND The single nucleotide polymorphism (SNP) rs1465618 in THADA at 2p21 has been identified as being associated with prostate cancer (PCa) risk in Europeans; however, it is not clear whether the SNP is related to PCa risk in multiple populations. We investigated the association of rs1465618 in THADA with PCa in a Chinese population and carried out a meta-analysis in multiple populations, testing the relevance of this SNP for PCa risk. PATIENTS AND METHODS We genotyped the SNP using high resolution melting (HRM) analysis and assessed its association with PCa risk in a case-control study of 289 PCa patients and 288 controls in a Chinese population. A meta-analysis was carried out with 36,313 PCa patients and 36,485 controls to evaluate the association of rs1465618 with PCa risk in multiple populations. RESULTS rs1465618 in THADA was significantly associated with PCa risk (p = 0.026; odds ratio (OR) 1.327, 95% confidence interval (CI) 1.035-1.700). Furthermore, the rs1465618 variant genotype was associated with PCa aggressiveness (p = 0.044; OR = 2.053, 95% CI = 1.015-6.602) in the Chinese population. The meta-analysis showed that rs1465618 was significantly associated with PCa risk in multiple populations (p = 1.0×10(-8); OR = 1.127, 95% CI = 1.085-1.171). CONCLUSION Our results showed that rs1465618 in THADA may be a shared susceptibility variant for PCa in multiple populations. THADA gene polymorphisms may impact PCa susceptibility and progression.
Collapse
Affiliation(s)
- Fan Zhao
- The Fifth School of Clinical Medicine, Peking University, Beijing, China [corrected]
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Munretnam K, Alex L, Ramzi NH, Chahil JK, Kavitha IS, Hashim NAN, Lye SH, Velapasamy S, Ler LW. Association of genetic and non-genetic risk factors with the development of prostate cancer in Malaysian men. Mol Biol Rep 2014; 41:2501-8. [PMID: 24443231 DOI: 10.1007/s11033-014-3107-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2013] [Accepted: 01/07/2014] [Indexed: 12/31/2022]
Abstract
There is growing global interest to stratify men into different levels of risk to developing prostate cancer, thus it is important to identify common genetic variants that confer the risk. Although many studies have identified more than a dozen common genetic variants which are highly associated with prostate cancer, none have been done in Malaysian population. To determine the association of such variants in Malaysian men with prostate cancer, we evaluated a panel of 768 SNPs found previously associated with various cancers which also included the prostate specific SNPs in a population based case control study (51 case subjects with prostate cancer and 51 control subjects) in Malaysian men of Malay, Chinese and Indian ethnicity. We identified 21 SNPs significantly associated with prostate cancer. Among these, 12 SNPs were strongly associated with increased risk of prostate cancer while remaining nine SNPs were associated with reduced risk. However, data analysis based on ethnic stratification led to only five SNPs in Malays and 3 SNPs in Chinese which remained significant. This could be due to small sample size in each ethnic group. Significant non-genetic risk factors were also identified for their association with prostate cancer. Our study is the first to investigate the involvement of multiple variants towards susceptibility for PC in Malaysian men using genotyping approach. Identified SNPs and non-genetic risk factors have a significant association with prostate cancer.
Collapse
Affiliation(s)
- Khamsigan Munretnam
- INFOVALLEY Group of Companies, INFOVALLEY® Life Sciences Sdn. Bhd., Unit 3 & 4, Level 7, Block C, Mines Waterfront Business Park, 43300, Seri Kembangan, Selangor, Malaysia
| | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Na R, Liu F, Zhang P, Ye D, Xu C, Shao Q, Qi J, Wang X, Chen Z, Wang M, He D, Wang Z, Zhou F, Yuan J, Gao X, Wei Q, Yang J, Jiao Y, Ou-Yang J, Zhu Y, Wu Q, Chen H, Lu D, Shi R, Lin X, Jiang H, Wang Z, Jiang D, Sun J, Zheng SL, Ding Q, Mo Z, Sun Y, Xu J. Evaluation of reported prostate cancer risk-associated SNPs from genome-wide association studies of various racial populations in Chinese men. Prostate 2013; 73:1623-35. [PMID: 24038036 PMCID: PMC3928594 DOI: 10.1002/pros.22629] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/02/2012] [Accepted: 11/16/2012] [Indexed: 11/06/2022]
Abstract
BACKGROUND Several genome-wide association studies (GWAS) of prostate cancer (PCa) have identified many single nucleotide polymorphisms (SNPs) that are significantly associated with PCa risk in various racial groups. The objective of this study is to evaluate which of these SNPs are associated with PCa risk in Chinese men and estimate their strength of association. METHODS All SNPs that were reported to be associated with PCa risk in GWAS from populations of European, African American, Japanese, and Chinese descent were evaluated in 1,922 PCa cases and 2,175 controls selected from the Chinese Consortium for Prostate Cancer Genetics (ChinaPCa). A logistic regression analysis was used to estimate allelic odds ratios (ORs) of these SNPs for PCa. RESULTS Among the 53 SNPs, 50 were polymorphic in the Chinese population. Of which, 10 and 24 SNPs were significantly associated with PCa risk in Chinese men at P < 0.001 and <0.05, respectively. These 24 significant SNPs included 17, 5, and 2 SNPs that were originally discovered in European, Japanese, and Chinese descent, respectively. The estimated ORs ranged from 1.10 to 1.49 and the direction of association was consistent with previous studies. When ORs were estimated separately for PCa with Gleason score ≤7 and ≥8, a marginally significant difference in ORs was found only for two of the 24 SNPs (P = 0.02 and 0.04). CONCLUSION About half of PCa risk-associated SNPs identified in GWAS of various populations are associated with PCa risk in Chinese men. Information on PCa risk-associated SNPs and their ORs may facilitate risk assessment of PCa risk in Chinese men.
Collapse
Affiliation(s)
- Rong Na
- Fudan Institute of Urology, Huashan Hospital, Fudan
University, Shanghai, PR China
| | - Fang Liu
- Fudan Institute of Urology, Huashan Hospital, Fudan
University, Shanghai, PR China
- State Key Laboratory of Genetic Engineering, School of Life
Sciences, Fudan University, Shanghai, PR China
- Center for Genetic Epidemiology, School of Life Sciences,
Fudan University, Shanghai, PR China
| | - Penyin Zhang
- State Key Laboratory of Genetic Engineering, School of Life
Sciences, Fudan University, Shanghai, PR China
- Center for Genetic Epidemiology, School of Life Sciences,
Fudan University, Shanghai, PR China
| | - Dingwei Ye
- Department of Urology, Fudan University Shanghai Cancer
Center, Shanghai, PR China
- Department of Oncology, Shanghai Medical College, Fudan
University, Shanghai, PR China
| | - Chuanliang Xu
- Department of Urology, Shanghai Changhai Hospital, Second
Military Medical University, Shanghai, PR China
| | - Qiang Shao
- Department of Urology, Suzhou Municipal Hospital, Suzhou,
PR China
| | - Jun Qi
- Department of Urology, Xinhua Hospital, School of Medicine,
Shanghai Jiaotong University, Shanghai, PR China
| | - Xiang Wang
- Fudan Institute of Urology, Huashan Hospital, Fudan
University, Shanghai, PR China
| | - Zhiwen Chen
- Urology Institute of PLA, Southwest Hospital, Third
Military Medical University, Chongqing, PR China
| | - Meilin Wang
- Department of Molecular and Genetic Toxicology, The Key
Laboratory of Modern Toxicology of Ministry of Education, School of Public Health,
Nanjing Medical University, Nanjing, PR China
- State Key Laboratory of Reproductive Medicine, Nanjing
Medical University, Nanjing, PR China
| | - Dalin He
- Department of Urology, The First Affiliated Hospital of
Medical College of Xi’an Jiaotong University, Xi’an, PR China
| | - Zhong Wang
- Department of Urology, Ninth People’s Hospital,
School of Medicine, Shanghai Jiaotong University, Shanghai, PR China
| | - Fangjian Zhou
- State Key Laboratory of Oncology in Southern China,
Guangzhou, PR China
- Department of Urology, Cancer Center, Sun Yat-Sen
University, Guangzhou, PR China
| | - Jianlin Yuan
- Department of Urology, Xijing Hospital, The Fourth
Military Medical University, Xi’an, PR China
| | - Xin Gao
- Department of Urology, The Third Affiliated Hospital, Sun
Yat-sen University, Guangzhou, PR China
| | - Qiang Wei
- Department of Urology, West China Hospital, Sichuan
University, Chengdu, Sichuan, PR China
| | - Jin Yang
- Department of Cell Biology, Third Military Medical
University, Chongqing, PR China
| | - Yang Jiao
- Department of Urology, Xinhua Hospital, School of Medicine,
Shanghai Jiaotong University, Shanghai, PR China
| | - Jun Ou-Yang
- Department of Urology, First People’s Hospital,
Suzhou University, Suzhou, PR China
| | - Yao Zhu
- Department of Urology, Fudan University Shanghai Cancer
Center, Shanghai, PR China
- Department of Oncology, Shanghai Medical College, Fudan
University, Shanghai, PR China
| | - Qijun Wu
- State Key Laboratory of Oncogene and Related Genes,
Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of
Medicine, Shanghai, PR China
| | - Hongyan Chen
- State Key Laboratory of Genetic Engineering, School of Life
Sciences, Fudan University, Shanghai, PR China
- Center for Genetic Epidemiology, School of Life Sciences,
Fudan University, Shanghai, PR China
| | - Daru Lu
- State Key Laboratory of Genetic Engineering, School of Life
Sciences, Fudan University, Shanghai, PR China
- Center for Genetic Epidemiology, School of Life Sciences,
Fudan University, Shanghai, PR China
| | - Rong Shi
- School of Public Health, Shanghai Jiaotong University,
Shanghai, PR China
| | - Xiaoling Lin
- Fudan Institute of Urology, Huashan Hospital, Fudan
University, Shanghai, PR China
- State Key Laboratory of Genetic Engineering, School of Life
Sciences, Fudan University, Shanghai, PR China
- Center for Genetic Epidemiology, School of Life Sciences,
Fudan University, Shanghai, PR China
| | - Haowen Jiang
- Fudan Institute of Urology, Huashan Hospital, Fudan
University, Shanghai, PR China
| | - Zhong Wang
- Center for Cancer Genomics, Wake Forest School of
Medicine, Winston-Salem, North Carolina
| | - Deke Jiang
- State Key Laboratory of Genetic Engineering, School of Life
Sciences, Fudan University, Shanghai, PR China
- Center for Genetic Epidemiology, School of Life Sciences,
Fudan University, Shanghai, PR China
| | - Jielin Sun
- Center for Cancer Genomics, Wake Forest School of
Medicine, Winston-Salem, North Carolina
| | - S. Lilly Zheng
- Center for Cancer Genomics, Wake Forest School of
Medicine, Winston-Salem, North Carolina
| | - Qing Ding
- Fudan Institute of Urology, Huashan Hospital, Fudan
University, Shanghai, PR China
| | - Zengnan Mo
- Center for Genomic and Personalized Medicine, Guangxi
Medical University, Nanning, Guangxi, PR China
- Department of Urology and Nephrology, The First
Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, PR China
| | - Yinghao Sun
- Department of Urology, Shanghai Changhai Hospital, Second
Military Medical University, Shanghai, PR China
- Correspondence to: Yinghao Sun, Department of
Urology, Shanghai Changhai Hospital, Second Military Medical University, 168
Changhai Road, Shanghai, PR China.
| | - Jianfeng Xu
- Fudan Institute of Urology, Huashan Hospital, Fudan
University, Shanghai, PR China
- State Key Laboratory of Genetic Engineering, School of Life
Sciences, Fudan University, Shanghai, PR China
- Center for Genetic Epidemiology, School of Life Sciences,
Fudan University, Shanghai, PR China
- Center for Cancer Genomics, Wake Forest School of
Medicine, Winston-Salem, North Carolina
- Correspondence to: Jianfeng Xu, Fudan Institute
of Urology, Huashan Hospital, Fudan University, 12 Mid-Wulumuqi Road, Shanghai,
PR China.
| |
Collapse
|
26
|
Jiang H, Liu F, Wang Z, Na R, Zhang L, Wu Y, Zheng J, Lin X, Jiang D, Sun J, Zheng SL, Ding Q, Xu J. Prediction of prostate cancer from prostate biopsy in Chinese men using a genetic score derived from 24 prostate cancer risk-associated SNPs. Prostate 2013; 73:1651-9. [PMID: 23868750 PMCID: PMC3909876 DOI: 10.1002/pros.22661] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/18/2012] [Accepted: 02/15/2013] [Indexed: 11/11/2022]
Abstract
BACKGROUND Twenty-four prostate cancer (PCa) risk-associated single nucleotide polymorphisms (SNPs) in Chinese men have been cataloged. We evaluated whether these SNPs can independently predict outcomes of prostate biopsy, and improve the predictive performance of existing clinical variables. METHODS Three hundred eight consecutive patients that underwent prostate biopsy for detection of PCa at Huashan Hospital, Shanghai, China between April 2011 and August 2012 were recruited. Clinical variables such as serum prostate-specific antigen (PSA) levels and peripheral blood samples were collected prior to a 10-core biopsy. A genetic score based on these 24 PCa associated SNPs was calculated for each individual. RESULTS Among 308 patients underwent prostate biopsy, 141 (45.8%) were diagnosed with PCa. Genetic score was significantly higher in patients with PCa (median = 1.30) than without (median = 0.89), P = 3.81 × 10(-6). The difference remained significant after adjusting for age and total PSA, P = 0.007. The PCa detection rate increased with increasing genetic score; 26.3%, 43.2%, and 60.0% for men with lower (<0.5), average (0.5-1.5), and higher (>1.5) genetic score, respectively, P(-trend) = 0.0003. For patients with moderately elevated PSA levels (1.6-20 ng/ml), the PCa detection rate was 31.2% overall and was 16.7%, 31.2%, and 40.9% for men with lower (<0.5), average (0.5-1.5), and higher (>1.5) genetic score, respectively, P(-trend) = 0.03. For patients with PSA ≥ 20 ng/ml, however, the PCa detection rates were high (>69%) regardless of genetic score. CONCLUSION A genetic score based on PCa risk-associated SNPs is an independent predictor of prostate biopsy outcomes in Chinese men and may be helpful to determine the need for prostate biopsy among patients within a "gray zone" of PCa risk.
Collapse
Affiliation(s)
- Haowen Jiang
- Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, P.R.China
| | - Fang Liu
- Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, P.R.China
- State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, P.R.China
- Center for Genetic Epidemiology, School of Life Sciences, Fudan University, Shanghai, P.R.China
| | - Zhong Wang
- Center for Cancer Genomics,Wake Forest School of Medicine,Winston-Salem, North Carolina
| | - Rong Na
- Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, P.R.China
- State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, P.R.China
- Center for Genetic Epidemiology, School of Life Sciences, Fudan University, Shanghai, P.R.China
- Center for Cancer Genomics,Wake Forest School of Medicine,Winston-Salem, North Carolina
| | - Limin Zhang
- Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, P.R.China
| | - Yishuo Wu
- Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, P.R.China
| | - Jie Zheng
- Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, P.R.China
| | - Xiaoling Lin
- Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, P.R.China
- State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, P.R.China
- Center for Genetic Epidemiology, School of Life Sciences, Fudan University, Shanghai, P.R.China
| | - Deke Jiang
- State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, P.R.China
- Center for Genetic Epidemiology, School of Life Sciences, Fudan University, Shanghai, P.R.China
| | - Jielin Sun
- Center for Cancer Genomics,Wake Forest School of Medicine,Winston-Salem, North Carolina
| | - S. Lilly Zheng
- Center for Cancer Genomics,Wake Forest School of Medicine,Winston-Salem, North Carolina
| | - Qiang Ding
- Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, P.R.China
- Correspondence to: Qiang Ding and Jianfeng Xu, Fudan Institute of Urology, Huashan Hospital, Fudan University, 12 Wulumuqi Rd. (M), Shanghai 200040, China. ;
| | - Jianfeng Xu
- Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, P.R.China
- State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, P.R.China
- Center for Genetic Epidemiology, School of Life Sciences, Fudan University, Shanghai, P.R.China
- Center for Cancer Genomics,Wake Forest School of Medicine,Winston-Salem, North Carolina
- Correspondence to: Qiang Ding and Jianfeng Xu, Fudan Institute of Urology, Huashan Hospital, Fudan University, 12 Wulumuqi Rd. (M), Shanghai 200040, China. ;
| |
Collapse
|
27
|
Genome-wide association study identifies genetic determinants of urine PCA3 levels in men. Neoplasia 2013; 15:448-53. [PMID: 23555189 DOI: 10.1593/neo.122144] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2012] [Revised: 02/06/2013] [Accepted: 02/07/2013] [Indexed: 01/22/2023] Open
Abstract
Prostate cancer gene 3 (PCA3) is a non-coding gene specifically overexpressed in prostate cancer (PCa) that has great potential as a clinical biomarker for predicting prostate biopsy outcome. However, genetic determinants of PCA3 expression level remain unknown. To investigate the association between genetic variants and PCA3 mRNA level, a genome-wide association study was conducted in 1371 men of European descent in the REduction by DUtasteride of prostate Cancer Events trial. First-voided urine specimens containing prostate cells were obtained after digital rectal examination. The PROGENSA PCA3 assay was used to determine PCA3 score in the urinary samples. A linear regression model was used to detect the associations between (single nucleotide polymorphisms) SNPs and PCA3 score under an additive genetic model, adjusting for age and population stratification. Two SNPs, rs10993994 in β-microseminoprotein at 10q11.23 and rs10424878 in kallikrein-related peptidase 2 at 19q13.33, were associated with PCA3 score at genome-wide significance level (P = 1.22 x 10(-9) and 1.06 x 10(-8), respectively). Men carrying the rs10993994 "T" allele or rs10424878 "A" allele had higher PCA3 score compared with men carrying rs10993994 "C" allele or rs10424878 "G" allele (β = 1.25 and 1.24, respectively). This is the first comprehensive search for genetic determinants of PCA3 score. The novel loci identified may provide insight into the molecular mechanisms of PCA3 expression as a potential marker of PCa.
Collapse
|
28
|
Association of a common variant at 10q26 and benign prostatic hyperplasia aggressiveness in han chinese descent. Biochem Res Int 2013; 2013:820849. [PMID: 23984071 PMCID: PMC3747368 DOI: 10.1155/2013/820849] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2013] [Accepted: 07/08/2013] [Indexed: 11/20/2022] Open
Abstract
Recent studies reported that rs2252004 at 10q26 was significantly associated with prostate cancer (PCa) risk in a Japanese population and was subsequently confirmed in a Chinese population. We aimed to assess the relationship between this locus and risk/aggressiveness of benign prostatic hyperplasia (BPH). The current study included 426 BPH cases and 1,008 controls from Xinhua Hospital in Shanghai, China. All BPH patients were treated with α-adrenergic blockers and 5α-reductase inhibitors for at least 9 months. Associations between rs2252004 and BPH risk/aggressiveness were tested using logistic regression. Associations between rs2252004 and clinical parameters including International Prostate Symptom Score (IPSS), total prostate volume (TPV), total PSA (tPSA), and free PSA (fPSA) were evaluated by linear regression. Allele “A” in rs2252004 was significantly associated with increased risk for aggressiveness of BPH in a Chinese population (OR = 1.42, 95% CI: 1.04–1.96, P = 0.03). Patients with the genotype “A/A” (homozygous minor allele) had an increase of IPSS and TPV after treatment (P = 0.045 and 0.024, resp.). No association was observed between rs2252004, BPH risk, and baseline clinicopathological traits (All P > 0.05). Our study is the first to show that rs2252004 at 10q26 was associated with BPH aggressiveness and efficacy of BPH treatment.
Collapse
|
29
|
Qi J, Tian L, Chen Z, Wang L, Tao S, Gu X, Na R, Jiao Y, Kang J, Zheng S, Xu J, Sun J. Genetic variants in 2q31 and 5p15 are associated with aggressive benign prostatic hyperplasia in a Chinese population. Prostate 2013; 73:1182-90. [PMID: 23620269 DOI: 10.1002/pros.22666] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/17/2012] [Accepted: 02/26/2013] [Indexed: 11/06/2022]
Abstract
BACKGROUND Benign prostatic hyperplasia (BPH) is a common disease prevalent in elderly men. However, the genetic determinants of BPH remain unclear. Because BPH and prostate cancer (PCa) share some common pathological characteristics, we investigated whether susceptibility loci for PCa contributed to BPH risk and BPH aggressiveness in Chinese men. METHODS Fourteen SNPs associated with PCa risk in a Chinese population were genotyped in 426 BPH cases (184 aggressive and 242 non-aggressive BPH cases) and 1,008 controls. The association between the SNPs and BPH risk/aggressiveness was estimated using logistic regression analysis. In addition, effects of the 14 SNPs on BPH related clinical traits, including International Prostate Symptom Score (IPSS), prostate volume, total PSA, and free PSA were evaluated using linear regression analysis. RESULTS Two SNPs, rs12621278 in ITGA6 at 2q31 (OR = 0.82, P = 0.05) and rs339331 in RFX6 at 6q22 (OR = 1.22, P = 0.04) were significantly associated with BPH. In addition, rs12621278 (OR = 0.73, P = 0.05) and rs12653946, 13 kb upstream of IRX4 at 5p15 (OR = 1.40, 0.03), were significantly associated with aggressive BPH. Moreover, the risk allele of rs12621278 (G) and rs12653946 (T) for aggressive BPH were significantly associated with elevated IPSS after treatment (P = 0.01). CONCLUSIONS This is the first systematic investigation on the contributions of PCa susceptibility loci to risk and aggressiveness of BPH. Our findings advance our understanding of the genetic basis of BPH, especially aggressive BPH. In addition, our results provide new insights into the genetic determinants shared between BPH and PCa.
Collapse
Affiliation(s)
- Jun Qi
- Department of Urology, Xinhua Hospital, Medical School of Shanghai Jiaotong University, Shanghai 200092, China.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Xu J, Sun J, Zheng SL. Prostate cancer risk-associated genetic markers and their potential clinical utility. Asian J Androl 2013; 15:314-22. [PMID: 23564047 PMCID: PMC3739659 DOI: 10.1038/aja.2013.42] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2013] [Revised: 03/16/2013] [Accepted: 03/18/2013] [Indexed: 02/02/2023] Open
Abstract
Prostate cancer (PCa) is one of the most common cancers among men in Western developed countries and its incidence has increased considerably in many other parts of the world, including China. The etiology of PCa is largely unknown but is thought to be multifactorial, where inherited genetics plays an important role. In this article, we first briefly review results from studies of familial aggregation and genetic susceptibility to PCa. We then recap key findings of rare and high-penetrance PCa susceptibility genes from linkage studies in PCa families. We devote a significant portion of this article to summarizing discoveries of common and low-penetrance PCa risk-associated single-nucleotide polymorphisms (SNPs) from genetic association studies in PCa cases and controls, especially those from genome-wide association studies (GWASs). A strong focus of this article is to review the literature on the potential clinical utility of these implicated genetic markers. Most of these published studies described PCa risk estimation using a genetic score derived from multiple risk-associated SNPs and its utility in determining the need for prostate biopsy. Finally, we comment on the newly proposed concept of genetic score; the notion is to treat it as a marker for genetic predisposition, similar to family history, rather than a diagnostic marker to discriminate PCa patients from non-cancer patients. Available evidence to date suggests that genetic score is an objective and better measurement of inherited risk of PCa than family history. Another unique feature of this article is the inclusion of genetic association studies of PCa in Chinese and Japanese populations.
Collapse
Affiliation(s)
- Jianfeng Xu
- Fudan Institute of Urology, Huashan Hospital, Fudan UniversityFudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai 200040, China.
| | | | | |
Collapse
|
31
|
Hu Y, Zhong D, Pang F, Ning Q, Zhang Y, Li G, Wu J, Mo Z. HNF1b is involved in prostate cancer risk via modulating androgenic hormone effects and coordination with other genes. GENETICS AND MOLECULAR RESEARCH 2013; 12:1327-35. [DOI: 10.4238/2013.april.25.4] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
32
|
Lin X, Qu L, Chen Z, Xu C, Ye D, Shao Q, Wang X, Qi J, Chen Z, Zhou F, Wang M, Wang Z, He D, Wu D, Gao X, Yuan J, Wang G, Xu Y, Wang G, Dong P, Jiao Y, Yang J, Ou-Yang J, Jiang H, Zhu Y, Ren S, Zhang Z, Yin C, Wu Q, Zheng Y, Turner AR, Tao S, Na R, Ding Q, Lu D, Shi R, Sun J, Liu F, Zheng SL, Mo Z, Sun Y, Xu J. A novel germline mutation in HOXB13 is associated with prostate cancer risk in Chinese men. Prostate 2013; 73:169-75. [PMID: 22718278 PMCID: PMC3755486 DOI: 10.1002/pros.22552] [Citation(s) in RCA: 62] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/26/2012] [Accepted: 05/29/2012] [Indexed: 11/12/2022]
Abstract
BACKGROUND A rare mutation G84E in HOXB13 was recently identified to be associated with prostate cancer (PCa) in Caucasians. The goal of this study is to test association between HOXB13 genetic variants and PCa risk in Chinese men. METHODS All study subjects were part of the Chinese Consortium for Prostate Cancer Genetics (ChinaPCa). In the first stage, we screened for mutations by sequencing the HOXB13 coding region in 96 unrelated PCa patients. In stage 2, G84E and novel mutations found in stage 1 were genotyped in 671 PCa patients and 1,536 controls. In stage 3, mutation status in 751 additional PCa patients was imputed via haplotype. RESULTS The G84E mutation was not detected in this study. However, a novel mutation, G135E, was identified among 96 patients in stage 1. It was also observed twice in 575 additional PCa patients but not in 1,536 control subjects of stage 2. The frequency of G135E was significantly different between cases and controls, with a P-value of 0.027, based on Fisher's exact test. Haplotype estimation showed that G135E mutation carriers shared a unique haplotype that was not observed in other subjects. In stage 3, two more PCa patients were predicted to carry the G135E mutation. CONCLUSIONS We identified a novel rare mutation in the HOXB13 gene, G135E, which appears to be a founder mutation. This mutation is associated with increased PCa risk in Chinese men. Consistent with a previous report, our findings provide further evidence that rare mutations in HOXB13 contribute to PCa risk.
Collapse
Affiliation(s)
- Xiaoling Lin
- Fudan-VARICenter for Genetic Epidemiology, School of Life Sciences, Fudan University, Shanghai, PR China
- Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, PR China
| | - Lianxi Qu
- Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, PR China
| | - Zhuo Chen
- Center for Cancer Genomics, Wake Forest University School of Medicine, Winston-Salem, North Carolina
| | - Chuanliang Xu
- Departmentof Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China
| | - Dingwei Ye
- Departmentof Urology, Cancer Hospital, and Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
| | - Qiang Shao
- Departmentof Urology, Suzhou Municipal Hospital, Suzhou, PR China
| | - Xiang Wang
- Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, PR China
| | - Jun Qi
- Departmentof Urology, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, PR China
| | - Zhiwen Chen
- Urologyof Institute of PLA, Southwest Hospital, Third Military Medical University, C hongqing, China
| | - Fangjian Zhou
- State Key Laboratory of Oncology in Southern China, Guangzhou, China
- Departmentof Urology, Cancer Center, Sun Yat-Sen University, Guangzhou, China
| | - Meilin Wang
- Departmentof Molecular & Genetic Toxicology, the Key Laboratory of Modern Toxicology of Ministry of Education, School of Public Health, Nanjing Medical University, Nanjing, China
| | - Zhong Wang
- Departmentof Urology, Ninth People’s Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, PR China
| | - Dalin He
- Departmentof Urology, The First Affiliated Hospital of Medical College of Xi’an Jiaotong University, Xi’an, China
| | - Denglong Wu
- Departmentof Urology, Tongji Hospital, Tongji University, Shanghai, PR China
| | - Xin Gao
- Departmentof Urology, The Third Affiliated Hospital, Sun Yatsen University, Guangzhou, PR China
| | - Jianlin Yuan
- Departmentof Urology, Xijing Hospital, Forth Military Medical University, Xi’an, Shaanxi Province, PR China
| | - Gongxian Wang
- Departmentof Urology, The First Affiliated Hospital of Nanchang University, Jiangxi, PR China
| | - Yong Xu
- Departmentof Urology, Second Hospital of TianJin Medical University, TianJin Institute of Urology, Tianjin, China
| | - Guozeng Wang
- Departmentof Urology, Pudong Gongli Hospital, Shanghai, PR China
| | - Pei Dong
- State Key Laboratory of Oncology in Southern China, Guangzhou, China
- Departmentof Urology, Cancer Center, Sun Yat-Sen University, Guangzhou, China
| | - Yang Jiao
- Departmentof Urology, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, PR China
| | - Jin Yang
- Departmentof Cell Biology, Third Military Medical University, Chongqing, China
| | - Jun Ou-Yang
- Departmentof Urology, First People’s Hospital, Suzhou University, Suzhou, PR China
| | - Haowen Jiang
- Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, PR China
| | - Yao Zhu
- Departmentof Urology, Cancer Hospital, and Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
| | - Shancheng Ren
- Departmentof Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China
| | - Zhengdong Zhang
- Departmentof Molecular & Genetic Toxicology, the Key Laboratory of Modern Toxicology of Ministry of Education, School of Public Health, Nanjing Medical University, Nanjing, China
| | - Changjun Yin
- Departmentof Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
| | - Qijun Wu
- State Key Laboratory of Oncogene and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - Ying Zheng
- Shanghai Center for Disease Control and Prevention, Shanghai, China
| | - Aubrey R. Turner
- Center for Cancer Genomics, Wake Forest University School of Medicine, Winston-Salem, North Carolina
| | - Sha Tao
- Center for Cancer Genomics, Wake Forest University School of Medicine, Winston-Salem, North Carolina
| | - Rong Na
- Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, PR China
- Center for Cancer Genomics, Wake Forest University School of Medicine, Winston-Salem, North Carolina
| | - Qiang Ding
- Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, PR China
| | - Daru Lu
- Fudan-VARICenter for Genetic Epidemiology, School of Life Sciences, Fudan University, Shanghai, PR China
- State Key Laboratory of Genetic Engineering, Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, PR China
| | - Rong Shi
- Schoolof Public Health, Shanghai Jiaotong University, Shanghai, PR China
| | - Jielin Sun
- Center for Cancer Genomics, Wake Forest University School of Medicine, Winston-Salem, North Carolina
| | - Fang Liu
- Fudan-VARICenter for Genetic Epidemiology, School of Life Sciences, Fudan University, Shanghai, PR China
- Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, PR China
| | - S. Lilly Zheng
- Center for Cancer Genomics, Wake Forest University School of Medicine, Winston-Salem, North Carolina
| | - Zengnan Mo
- Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi, PR China
- Departmentof Urology and Nephrology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, PR China
| | - Yinghao Sun
- Departmentof Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China
| | - Jianfeng Xu
- Fudan-VARICenter for Genetic Epidemiology, School of Life Sciences, Fudan University, Shanghai, PR China
- Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, PR China
- Center for Cancer Genomics, Wake Forest University School of Medicine, Winston-Salem, North Carolina
- Correspondence to: Dr. Jianfeng Xu, MD, DrPH, Fudan Institute of Urology, Fudan University, Shanghai 200040, China.
| |
Collapse
|
33
|
Genome-wide association study in Chinese men identifies two new prostate cancer risk loci at 9q31.2 and 19q13.4. Nat Genet 2012; 44:1231-5. [PMID: 23023329 DOI: 10.1038/ng.2424] [Citation(s) in RCA: 143] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2012] [Accepted: 09/05/2012] [Indexed: 12/22/2022]
Abstract
Prostate cancer risk-associated variants have been reported in populations of European descent, African-Americans and Japanese using genome-wide association studies (GWAS). To systematically investigate prostate cancer risk-associated variants in Chinese men, we performed the first GWAS in Han Chinese. In addition to confirming several associations reported in other ancestry groups, this study identified two new risk-associated loci for prostate cancer on chromosomes 9q31.2 (rs817826, P = 5.45 × 10(-14)) and 19q13.4 (rs103294, P = 5.34 × 10(-16)) in 4,484 prostate cancer cases and 8,934 controls. The rs103294 marker at 19q13.4 is in strong linkage equilibrium with a 6.7-kb germline deletion that removes the first six of seven exons in LILRA3, a gene regulating inflammatory response, and was significantly associated with the mRNA expression of LILRA3 in T cells (P < 1 × 10(-4)). These findings may advance the understanding of genetic susceptibility to prostate cancer.
Collapse
|
34
|
Zheng J, Liu F, Lin X, Wang X, Ding Q, Jiang H, Chen H, Lu D, Jin G, Hsing AW, Shao Q, Qi J, Ye Y, Wang Z, Gao X, Wang G, Chu LW, OuYang J, Huang Y, Chen Y, Gao Y, Shi R, Wu Q, Wang M, Zhang Z, Hu Y, Sun J, Zheng SL, Gao X, Xu C, Mo Z, Sun Y, Xu J. Predictive performance of prostate cancer risk in Chinese men using 33 reported prostate cancer risk-associated SNPs. Prostate 2012; 72:577-83. [PMID: 21796652 PMCID: PMC3232337 DOI: 10.1002/pros.21462] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/28/2011] [Accepted: 06/29/2011] [Indexed: 11/07/2022]
Abstract
BACKGROUND Genome-wide association studies (GWAS) have identified more than 30 single nucleotide polymorphisms (SNPs) that were reproducibly associated with prostate cancer (PCa) risk in populations of European descent. In aggregate, these variants have shown potential to predict risk for PCa in European men. However, their utility for PCa risk prediction in Chinese men is unknown. METHODS We selected 33 PCa risk-related SNPs that were originally identified in populations of European descent. Genetic scores were estimated for subjects in a Chinese case-control study (1,108 cases and 1,525 controls) based on these SNPs. To assess the performance of the genetic score on its ability to predict risk for PCa, we calculated area under the curve (AUC) of the receiver operating characteristic (ROC) in combination with 10-fold cross-validation. RESULTS The genetic score was significantly higher for cases than controls (P = 5.91 × 10(-20)), and was significantly associated with risk of PCa in a dose-dependent manner (P for trend: 4.78 × 10(-18)). The AUC of the genetic score was 0.604 for risk prediction of PCa in Chinese men. When ORs derived from this Chinese study population were used to calculate genetic score, the AUCs were 0.631 for all 33 SNPs and 0.617 when using only the 11 significant SNPs. CONCLUSION Our results indicate that genetic variants related to PCa risk may be useful for risk prediction in Chinese men. Prospective studies are warranted to further evaluate these findings.
Collapse
Affiliation(s)
- Jie Zheng
- Department of Urology, Huashan Hospital, Fudan University, Shanghai, PR China
| | - Fang Liu
- Fudan-VARI Center for Genetic Epidemiology, School of Life Sciences, Fudan University, Shanghai, PR China
| | - Xiaoling Lin
- Fudan-VARI Center for Genetic Epidemiology, School of Life Sciences, Fudan University, Shanghai, PR China
| | - Xiang Wang
- Department of Urology, Huashan Hospital, Fudan University, Shanghai, PR China
| | - Qiang Ding
- Department of Urology, Huashan Hospital, Fudan University, Shanghai, PR China
| | - Haowen Jiang
- Department of Urology, Huashan Hospital, Fudan University, Shanghai, PR China
| | - Hongyan Chen
- Fudan-VARI Center for Genetic Epidemiology, School of Life Sciences, Fudan University, Shanghai, PR China
- State Key Laboratory of Genetic Engineering, Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, PR China
| | - Daru Lu
- Fudan-VARI Center for Genetic Epidemiology, School of Life Sciences, Fudan University, Shanghai, PR China
- State Key Laboratory of Genetic Engineering, Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, PR China
| | - Guangfu Jin
- Center for Cancer Genomics, Wake Forest University School of Medicine, Winston-Salem, NC
| | - Ann W. Hsing
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Qiang Shao
- Department of Urology, Suzhou Municipal Hospital, Suzhou, PR China
| | - Jun Qi
- Department of Urology, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, PR China
| | - Yu Ye
- Department of Urology, The First Affiliated Hospital, Guangxi Medical University, Guangxi, PR China
| | - Zhong Wang
- Department of Urology, Ninth People's Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, PR China
| | - Xin Gao
- Department of Urology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, PR China
| | - Guozeng Wang
- Department of Urology, Pudong Gongli Hospital, Shanghai, PR China
| | - Lisa W. Chu
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Jun OuYang
- Department of Urology, First People's Hospital, Suzhou University, Suzhou, PR China
| | - Yichen Huang
- Department of Urology, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, PR China
| | - Yanbo Chen
- Department of Urology, Ninth People's Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, PR China
| | - Yutang Gao
- Shanghai Cancer Institute, Shanghai, PR China
| | - Rong Shi
- School of Public Health, Shanghai Jiaotong University, Shanghai, PR China
| | - Qijun Wu
- School of Public Health, Shanghai Jiaotong University, Shanghai, PR China
| | - Meilin Wang
- Department of Molecular & Genetic Toxicology, School of Public Health, Cancer Center, Nanjing Medical University, Nanjing, PR China
| | - Zhengdong Zhang
- Department of Molecular & Genetic Toxicology, School of Public Health, Cancer Center, Nanjing Medical University, Nanjing, PR China
| | - Yanlin Hu
- Department of Urology, The First Affiliated Hospital, Guangxi Medical University, Guangxi, PR China
| | - Jielin Sun
- Fudan-VARI Center for Genetic Epidemiology, School of Life Sciences, Fudan University, Shanghai, PR China
- Center for Cancer Genomics, Wake Forest University School of Medicine, Winston-Salem, NC
| | - S. Lilly Zheng
- Fudan-VARI Center for Genetic Epidemiology, School of Life Sciences, Fudan University, Shanghai, PR China
- Center for Cancer Genomics, Wake Forest University School of Medicine, Winston-Salem, NC
| | - Xu Gao
- Department of Urology, Changhai Hospital, The Second Military Medical University, Shanghai, PR China
| | - Chuanliang Xu
- Department of Urology, Changhai Hospital, The Second Military Medical University, Shanghai, PR China
| | - Zengnan Mo
- Department of Urology, The First Affiliated Hospital, Guangxi Medical University, Guangxi, PR China
| | - Yinghao Sun
- Department of Urology, Changhai Hospital, The Second Military Medical University, Shanghai, PR China
- Correspondence to: Yinghao Sun, Department of Urology, Changhai Hospital, The Second Military Medical University, 168 Changhai Road, Shanghai 200433, PR China, ., or Jianfeng Xu, Center for Cancer Genomics, Wake Forest University School of Medicine, Winston-Salem, NC, USA,
| | - Jianfeng Xu
- Department of Urology, Huashan Hospital, Fudan University, Shanghai, PR China
- Fudan-VARI Center for Genetic Epidemiology, School of Life Sciences, Fudan University, Shanghai, PR China
- State Key Laboratory of Genetic Engineering, Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, PR China
- Center for Cancer Genomics, Wake Forest University School of Medicine, Winston-Salem, NC
- Department of Urology, Wake Forest University School of Medicine, Winston-Salem, NC
- Van Andel Research Institute, Grand Rapids, MI
- Correspondence to: Yinghao Sun, Department of Urology, Changhai Hospital, The Second Military Medical University, 168 Changhai Road, Shanghai 200433, PR China, ., or Jianfeng Xu, Center for Cancer Genomics, Wake Forest University School of Medicine, Winston-Salem, NC, USA,
| |
Collapse
|
35
|
|
36
|
Wang M, Liu F, Hsing AW, Wang X, Shao Q, Qi J, Ye Y, Wang Z, Chen H, Gao X, Wang G, Chu LW, Ding Q, OuYang J, Gao X, Huang Y, Chen Y, Gao YT, Zhang ZF, Rao J, Shi R, Wu Q, Zhang Y, Jiang H, Zheng J, Hu Y, Guo L, Lin X, Tao S, Jin G, Sun J, Lu D, Zheng SL, Sun Y, Mo Z, Yin C, Zhang Z, Xu J. Replication and cumulative effects of GWAS-identified genetic variations for prostate cancer in Asians: a case-control study in the ChinaPCa consortium. Carcinogenesis 2011; 33:356-60. [PMID: 22114074 DOI: 10.1093/carcin/bgr279] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
A recent genome-wide association study has identified five new genetic variants for prostate cancer susceptibility in a Japanese population, but it is unknown whether these newly identified variants are associated with prostate cancer risk in other populations, including Chinese men. We genotyped these five variants in a case-control study of 1524 patients diagnosed with prostate cancer and 2169 control subjects from the Chinese Consortium for Prostate Cancer Genetics (ChinaPCa). We found that three of the five genetic variants were associated with prostate cancer risk (P = 4.33 × 10(-8) for rs12653946 at 5p15, 4.43 × 10(-5) for rs339331 at 6q22 and 8.42 × 10(-4) for rs9600079 at 13q22, respectively). A cumulative effect was observed in a dose-dependent manner with increasing numbers of risk variant alleles (P(trend) = 2.58 × 10(-13)), and men with 5-6 risk alleles had a 2-fold higher risk of prostate cancer than men with 0-2 risk alleles (odds ratio = 2.26, 95% confidence interval = 1.78-2.87). Furthermore, rs339331 T allele was significantly associated with RFX6 and GPRC6A higher messenger RNA expression, compared with the C allele. However, none of the variants was associated with clinical stage, Gleason score or family history. These results provide further evidence that the risk loci identified in Japanese men also contribute to prostate cancer susceptibility in Chinese men.
Collapse
Affiliation(s)
- Meilin Wang
- State Key Laboratory of Reproductive Medicine, Nanjing Medical University, 140 Hanzhong Road, Nanjing 210029, People's Republic of China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|